World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
23981
World Ranking
17514
National Ranking
8765

Overview

Suzanne George is affiliated with Harvard University in the United States and specializes primarily in the field of Medicine. Their research spans a variety of subfields including Pulmonary and Respiratory Medicine, Gastroenterology, Oncology, Surgery, and Cancer Research.

The main topics covered in Suzanne George's work include:

  • Gastrointestinal Tumor Research and Treatment
  • Sarcoma Diagnosis and Treatment
  • Gastric Cancer Management and Outcomes
  • Gastrointestinal disorders and treatments
  • Cancer Genomics and Diagnostics
  • Vascular Tumors and Angiosarcomas
  • Ethics in Clinical Research

Some of the recent papers authored or co-authored by Suzanne George are:

  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • NCCN Guidelines Insights: Soft Tissue Sarcoma, Version 1.2021, 2020, Journal of the National Comprehensive Cancer Network
  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial, 2020, The Lancet Oncology
  • Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities, 2021, Cancer
  • NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021, 2021, Journal of the National Comprehensive Cancer Network

Frequent co-authors working alongside Suzanne George include:

  • Michael C. Heinrich
  • Robin L. Jones
  • Margaret von Mehren
  • Sebastian Bauer
  • César Serrano

The scientist's publications are often found in the following venues:

  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • Annals of Oncology
  • Cancer Research
  • European Journal of Cancer

Best Publications

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

    Tammy F Chu;Tammy F Chu;Maria A Rupnick;Maria A Rupnick;Risto Kerkela;Susan M Dallabrida

  • Soft Tissue Sarcoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology

    Margaret von Mehren;R. Lor Randall;Robert S. Benjamin;Sarah Boles

  • Uterine Neoplasms, Version 1.2018: Clinical practice guidelines in oncology

    Wui Jin Koh;Nadeem R. Abu-Rustum;Sarah Bean;Kristin Bradley

  • Surgical Management of Advanced Gastrointestinal Stromal Tumors After Treatment With Targeted Systemic Therapy Using Kinase Inhibitors

    Chandrajit P. Raut;Matthew Posner;Jayesh Desai;Jeffrey A. Morgan

  • Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

    Jayesh Desai;Leila Yassa;Ellen Marqusee;Suzanne George

  • Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.

    S. George;J.Y. Blay;P.G. Casali;A. Le Cesne

  • Meta-analysis of Vascular and Neoplastic Events Associated with Tamoxifen

    R. Scott Braithwaite;Rowan T. Chlebowski;Joseph Lau;Suzanne George

  • Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

    Suzanne George;Diana Miao;Diana Miao;George D. Demetri;Dennis Adeegbe

  • Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.

    Sosipatros A. Boikos;Alberto S. Pappo;J. Keith Killian;Michael P. LaQuaglia

  • Multicenter Phase II Trial of Sunitinib in the Treatment of Nongastrointestinal Stromal Tumor Sarcomas

    Suzanne George;Priscilla Merriam;Robert G. Maki;Annick D. Van den Abbeele

  • Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial

    Suzanne George;Qian Wang;Michael C. Heinrich;Christopher L. Corless

  • Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.

    Jean Yves Blay;César Serrano;Michael C. Heinrich;John Zalcberg

  • Adolescent and young adult oncology. Clinical practice guidelines in oncology.

    Peter F. Coccia;Jessica Altman;Smita Bhatia;Scott C. Borinstein

  • Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.

    Michael C. Heinrich;Robin L. Jones;Margaret von Mehren;Patrick Schöffski

  • Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.

    Suzanne George;Constance Barysauskas;César Serrano;Titilope Oduyebo

  • Soft Tissue Sarcoma, Version 1.2021: Featured updates to the NCCN guidelines

    Margaret von Mehren;John M. Kane;Marilyn M. Bui;Edwin Choy

  • Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study

    Eytan Ben-Ami;Constance M. Barysauskas;Sarah Solomon;Kadija Tahlil

  • Soft Tissue and Uterine Leiomyosarcoma.

    Suzanne George;César Serrano;Martee L. Hensley;Isabelle Ray-Coquard

  • A Preeclampsia-like Syndrome Characterized by Reversible Hypertension and Proteinuria Induced by the Multitargeted Kinase Inhibitors Sunitinib and Sorafenib

    Tejas V. Patel;Jeffrey A. Morgan;George D. Demetri;Suzanne George

Frequent Co-Authors

George D. Demetri
George D. Demetri Dana-Farber Cancer Institute
Chandrajit P. Raut
Chandrajit P. Raut Brigham and Women's Hospital
Michael Heinrich
Michael Heinrich Oregon Health & Science University
Margaret von Mehren
Margaret von Mehren Fox Chase Cancer Center
Jason L. Hornick
Jason L. Hornick Brigham and Women's Hospital
Jonathan A. Fletcher
Jonathan A. Fletcher Brigham and Women's Hospital
Hans Gelderblom
Hans Gelderblom Leiden University Medical Center
Monica M. Bertagnolli
Monica M. Bertagnolli Brigham and Women's Hospital
John R. Zalcberg
John R. Zalcberg Monash University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees in healthcare can expand your professional opportunities beyond a traditional M.D. path. For many, a career in nursing offers several flexible, affordable, and rewarding alternatives.

One of the main considerations is how much is online nursing school. Tuition costs can vary, making it important to compare programs and find options that fit your budget.

Those who already have an RN license may benefit from cheap rn to bsn programs. These are designed for registered nurses seeking to advance their qualifications and open new career doors through a bachelor’s degree—often at an affordable rate.

For those interested in the highest echelons of nursing practice or academia, phd nursing programs online allow professionals to earn a doctorate while balancing work and study remotely.

Non-nursing graduates thinking of a fast track into nursing may consider direct entry msn programs online. These accelerated programs are crafted for those with a non-nursing background who wish to enter the nursing profession quickly.

Best Scientists Citing Suzanne George

Trending Scientists

Recently Published Articles